„Risiko-Gene“ wie zum Beispiel das ApoE-Gen – (lesen Sie hierzu unseren Beitrag Das ApoE-Gen – ein genetischer Risikofaktor für Alzheimer) können das Risiko, an Alzheimer zu erkranken, generell erhöhen. Doch bestimmte Genmutationen, die sogenannten „Ursachen-Gene“, können – in seltenen Fällen – die Erkrankung direkt verursachen. Drei dieser Ursachen-Gene sind wissenschaftlich bereits gut untersucht. …
Benzodiazepines, antidepressants, or antipsychotics: Researchers from Canada and Ireland have investigated how psychotropic drugs affect the cognition of older adults. The scientists have identified a link between regular use of benzodiazepines, certain antidepressants, and antipsychotics, and cognitive decline in older adults. As researchers from Canada and...
How effective is medical cannabis therapy with cannabidiol (CBD), the non-psychoactive component of the hemp plant, in adults with neuropsychiatric symptoms as a consequence of Alzheimer's dementia? A study from Colombia concluded that CBD-rich oil reduces the severity of symptoms in affected individuals as well as the emotional and physical care burden on relatives...
Taking various medications can serve as a possible early indicator of dementia at a younger age. Danish researchers came to this conclusion. They examined the medication intake of people who developed dementia before the age of 65. An often overlooked patient group is people with a rare form of dementia, the so-called „Young...
When people with dementia take antipsychotics, it is associated with an increased risk of adverse events such as stroke, heart failure, and pneumonia. This was the conclusion of researchers from Great Britain, Norway, and Greece. Researchers from Great Britain pointed to the current care situation in their study, published in 2024: „Despite safety concerns..."
Researchers at the University Hospital Erlangen have investigated how sedating medications affect potentially treatable falls in people with dementia. They analyzed data from 139 people with dementia living in five Bavarian nursing homes. When medications from certain drug classes are taken, this can, in people with dementia living in nursing homes, ...
Many people worldwide hope to halt memory loss in dementia. Since June 2021, the drug Aducanumab has been approved in the USA for the treatment of Alzheimer's disease – but not in Europe. In our fact check, you can learn more about its effectiveness and why strict scientific criteria are important when evaluating a...
A new drug has been approved in the US, sparking a global controversy within Alzheimer's research. This is because 10 out of 11 reviewers rejected the drug for the treatment of Alzheimer's disease. The dementia group of the Cochrane Institute provides a brief overview of the evidence for Aducanumab. For a long time, there was...
